UBS Asset Management Americas Inc. raised its position in shares of Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) by 50.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 405,336 shares of the company’s stock after buying an additional 136,404 shares during the period. UBS Asset Management Americas Inc. owned about 1.03% of Zeltiq Aesthetics worth $11,078,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of the stock. Legal & General Group Plc boosted its position in Zeltiq Aesthetics by 1.7% in the first quarter. Legal & General Group Plc now owns 4,963 shares of the company’s stock worth $134,000 after buying an additional 83 shares during the last quarter. Calamos Wealth Management LLC acquired a new position in Zeltiq Aesthetics during the second quarter worth about $200,000. BNP Paribas Arbitrage SA boosted its position in Zeltiq Aesthetics by 119.1% in the second quarter. BNP Paribas Arbitrage SA now owns 10,262 shares of the company’s stock worth $280,000 after buying an additional 5,579 shares during the last quarter. Quantbot Technologies LP acquired a new position in Zeltiq Aesthetics during the second quarter worth about $289,000. Finally, M&T Bank Corp acquired a new position in Zeltiq Aesthetics during the first quarter worth about $294,000.
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) traded up 0.78% on Friday, hitting $40.24. The stock had a trading volume of 508,005 shares. The firm’s 50-day moving average is $37.99 and its 200-day moving average is $30.77. Zeltiq Aesthetics Inc. has a 52-week low of $18.41 and a 52-week high of $40.98. The company has a market cap of $1.59 billion, a P/E ratio of 60.51 and a beta of 0.80.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.07. Zeltiq Aesthetics had a negative return on equity of 9.90% and a net margin of 9.54%. The company had revenue of $89.50 million for the quarter, compared to analysts’ expectations of $79.68 million. During the same period in the prior year, the business earned $0.03 EPS. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. Equities research analysts anticipate that Zeltiq Aesthetics Inc. will post ($0.13) earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on the company. Maxim Group boosted their price objective on Zeltiq Aesthetics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. Stifel Nicolaus lifted their target price on Zeltiq Aesthetics from $38.00 to $52.00 and gave the company a “buy” rating in a research report on Wednesday. Zacks Investment Research raised Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a research report on Saturday, July 23rd. TheStreet lowered Zeltiq Aesthetics from a “buy” rating to a “hold” rating in a research report on Friday, June 10th. Finally, Brean Capital reaffirmed a “buy” rating and set a $35.00 target price on shares of Zeltiq Aesthetics in a research report on Tuesday, June 21st. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $39.89.
In related news, CEO Mark J. Foley sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $31.21, for a total transaction of $312,100.00. Following the transaction, the chief executive officer now owns 325,940 shares of the company’s stock, valued at $10,172,587.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Carl Lamm sold 3,125 shares of the firm’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $40.00, for a total value of $125,000.00. Following the transaction, the vice president now directly owns 28,251 shares in the company, valued at approximately $1,130,040. The disclosure for this sale can be found here. Corporate insiders own 15.60% of the company’s stock.
Zeltiq Aesthetics Company Profile
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.